12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

AR-42 regulatory update

Arno said the European Commission granted Orphan Drug designation for AR-42 to treat neurofibromatosis type 2. The compound is in...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >